Literature DB >> 16540677

Identification of 14-3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis.

Yang Liu1, Hailan Liu, Baoguang Han, Jian-Ting Zhang.   

Abstract

Multidrug resistance (MDR) is a major obstacle to successful cancer treatment. To understand the mechanism of MDR, many cancer cell lines have been established, and various mechanisms of resistance, such as ATP-binding cassette (ABC) transporter-mediated drug efflux, have been discovered. Previously, a MDR cell line MCF7/AdVp3000 was selected from breast cancer cell line MCF7 against Adriamycin, and overexpression of ABCG2 was thought to cause MDR in this derivative cell line. However, ectopic overexpression of ABCG2 in MCF7 cells could not explain the extremely high drug resistance level of the selected MCF7/AdVp3000 cells. We hypothesized that MCF7/AdVp3000 cells must have other resistance mechanisms selected by Adriamycin. To test this hypothesis, we compared the global protein profiles between MCF7 and MCF7/AdVp3000 cells. Following two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionization-time of flight mass spectrometry analysis, 17 protein spots with differential levels between the two cell lines were identified. Although 14-3-3sigma, keratin 18, keratin 19, ATP synthase beta, protein disulfide isomerase, heat shock protein 27, cathepsin D, triose-phosphate isomerase, peroxiredoxin 6, and electron transfer flavoprotein were increased, nm23/H1, peroxiredoxin 2, nucleophosmin 1/B23, and inorganic pyrophosphatase were decreased in MCF7/AdVp3000 cells. The differential levels of these proteins were validated using Western blot. Furthermore, functional validation showed that the elevated 14-3-3sigma expression contributes considerably to the observed drug resistance in MCF7/AdVp3000 cells. We, thus, conclude that these proteins likely contribute to the resistance selected in the MCF7/AdVp3000 cells, and their altered expression in tumors may cause clinical resistance to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16540677     DOI: 10.1158/0008-5472.CAN-05-3801

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

1.  Human ABCC1 interacts and colocalizes with ATP synthase α, revealed by interactive proteomics analysis.

Authors:  Youyun Yang; Zhaomin Li; Wei Mo; Raghuram Ambadipudi; Randy J Arnold; Petra Hrncirova; Milos V Novotny; Elias Georges; Jian-Ting Zhang
Journal:  J Proteome Res       Date:  2012-01-18       Impact factor: 4.466

2.  14-3-3σ Contributes to Radioresistance By Regulating DNA Repair and Cell Cycle via PARP1 and CHK2.

Authors:  Yifan Chen; Zhaomin Li; Zizheng Dong; Jenny Beebe; Ke Yang; Liwu Fu; Jian-Ting Zhang
Journal:  Mol Cancer Res       Date:  2017-01-13       Impact factor: 5.852

3.  Determinants of 14-3-3σ protein dimerization and function in drug and radiation resistance.

Authors:  Zhaomin Li; Hui Peng; Li Qin; Jing Qi; Xiaobing Zuo; Jing-Yuan Liu; Jian-Ting Zhang
Journal:  J Biol Chem       Date:  2013-09-16       Impact factor: 5.157

4.  Proteomic studies in breast cancer (Review).

Authors:  Xian-Ju Qin; Bruce X Ling
Journal:  Oncol Lett       Date:  2012-01-18       Impact factor: 2.967

5.  Reversible epigenetic regulation of 14-3-3σ expression in acquired gemcitabine resistance by uhrf1 and DNA methyltransferase 1.

Authors:  Li Qin; Zizheng Dong; Jian-Ting Zhang
Journal:  Mol Pharmacol       Date:  2014-09-04       Impact factor: 4.436

6.  Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer.

Authors:  Yiqing Qu; Yie Yang; Baoyi Liu; Wei Xiao
Journal:  Med Oncol       Date:  2009-12-10       Impact factor: 3.064

7.  14-3-3sigma, the double-edged sword of human cancers.

Authors:  Zhaomin Li; Jing-Yuan Liu; Jian-Ting Zhang
Journal:  Am J Transl Res       Date:  2009-06-08       Impact factor: 4.060

8.  Role of 14-3-3σ in poor prognosis and in radiation and drug resistance of human pancreatic cancers.

Authors:  Zhaomin Li; Zizheng Dong; David Myer; Michele Yip-Schneider; Jianguo Liu; Ping Cui; C Max Schmidt; Jian-Ting Zhang
Journal:  BMC Cancer       Date:  2010-11-01       Impact factor: 4.430

9.  Dynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cells.

Authors:  Hui Peng; Jing Qi; Zizheng Dong; Jian-Ting Zhang
Journal:  PLoS One       Date:  2010-12-07       Impact factor: 3.240

10.  14-3-3sigma Modulates pancreatic cancer cell survival and invasiveness.

Authors:  Divas Neupane; Murray Korc
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.